Financial Comparison: BioRestorative Therapies (OTCMKTS:BRTXQ) and Emmaus Life Sciences (OTCMKTS:EMMA)
BioRestorative Therapies (OTCMKTS:BRTXQ) and Emmaus Life Sciences (NASDAQ:EMMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.
Valuation & Earnings
This table compares BioRestorative Therapies and Emmaus Life Sciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioRestorative Therapies||$110,000.00||308.47||-$12.52 million||N/A||N/A|
|Emmaus Life Sciences||$1.32 million||43.05||-$9.59 million||($11.16)||-0.10|
This table compares BioRestorative Therapies and Emmaus Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Emmaus Life Sciences||-489.28%||-511.05%||-209.39%|
Volatility & Risk
BioRestorative Therapies has a beta of 103.98, meaning that its stock price is 10,298% more volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for BioRestorative Therapies and Emmaus Life Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Emmaus Life Sciences||0||1||0||0||2.00|
Insider and Institutional Ownership
0.1% of Emmaus Life Sciences shares are owned by institutional investors. 12.2% of BioRestorative Therapies shares are owned by company insiders. Comparatively, 36.9% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
BioRestorative Therapies beats Emmaus Life Sciences on 6 of the 10 factors compared between the two stocks.
BioRestorative Therapies Company Profile
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.